|

Ivonescimab Clinical Trials

24 actively recruiting trials across 7 locations

Also known as: AK 112, AK-112, AK112, AK112/SMT112, Adapted Guided Stereotactic Body Radiotherapy, Anti-PD-1/Anti-VEGF Bispecific Antibody AK112, Anti-PD-1/VEGF Bispecific Antibody AK112, Chemotherapy, PD-1/VEGF Bispecific Antibody AK112, SMT 112, SMT-112, SMT112

Other14 trials

A Study of Ivonescimab in First-Line ES-SCLC
Phase 2
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Phase 1/2
AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
Phase 2
Adapted Guided Stereotactic Body Radiotherapy Combined with Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)
Phase 1/2
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Phase 2
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
Phase 2
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
Phase 1/2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
Phase 2
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Phase 2
Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Phase 2
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Phase 2
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
Phase 2
ctDNA-guided Treatment Decision-making
Phase 2

Houston, Texas3 trials

A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma

The University of Texas M. D. Anderson Cancer Center

Phase 1/2
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

The University of Texas M. D. Anderson Cancer Center

Phase 2
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

MD Anderson Cancer Center

Phase 2

Los Angeles, California2 trials

Ivonescimab for the Treatment of Thymic Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 2
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Cedars-Sinai Medical Center

Phase 2

Santa Monica, California1 trial

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

UCLA

Phase 2

Boston, Massachusetts1 trial

A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

Brigham and Women's Hospital

Phase 2

Ann Arbor, Michigan1 trial

Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

University of Michigan Comprehensive Cancer Center

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Ivonescimab in People With Endometrial and Cervical Cancers

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Phase 2

Fairfax, Virginia1 trial

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

NEXT Virginia

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.